This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Richard, V. Articles by Thuillez, C. Search for Related Content PubMed PubMed Citation Articles by Richard, V. Articles by Thuillez, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL Related Collections ACE/Angiotension receptors Other Vascular biology

(Circulation. 2001;104:750.)
© 2001 American Heart Association, Inc.

Brief Rapid Communications

Functional Evidence for a Role of Vascular Chymase in the Production of Angiotensin II in Isolated Human Arteries

Vincent Richard, PhD; Sonia Hurel-Merle, PharmD; Elizabeth Scalbert, PhD; Gilles Ferry, PhD; Françoise Lallemand, BSc; Jean-Paul Bessou, MD; Christian Thuillez, MD, PhD

From INSERM E9920 (IFRMP23), Rouen University Medical School (V.R., S.H.-M., F.L., J.-P.B., C.T.), Rouen, and the Institut de Recherches Internationales Servier (E.S., G.F.), Courbevoie, France.

Correspondence to Vincent Richard, INSERM E9920, 22 Boulevard Gambetta, 76183 Rouen Cedex, France. E-mail Vincent.Richard{at}univ-rouen.fr

Background— In human arteries, angiotensin-converting enzyme (ACE) inhibitors incompletely block the production of angiotensin (Ang) II from Ang I. This ACE-independent production of Ang II appears to be caused by serine proteases, one of which presumably is chymase. However, several serine proteases may produce Ang II, and the exact role of chymase in the vascular production of Ang II has never been directly evaluated using selective chymase inhibitors.

Methods and Results— Rings of human mammary arteries were subjected to either Ang I or the chymase-selective substrate [pro,¹¹ D-Ala¹²] Ang I in the absence or the presence of the ACE inhibitor captopril, the serine protease inhibitor chymostatin, or the selective chymase inhibitor C41. Captopril only partially inhibited (by 33%) the response to Ang I. In the absence of captopril, C41 markedly reduced (by 44%) the response to Ang I, and this effect was identical to that of chymostatin. C41 also significantly reduced the response to Ang I in the presence of captopril, although this inhibitory effect was slightly less than that of captopril in combination with chymostatin. [Pro,¹¹D-Ala¹²] Ang I induced potent contractions that were not affected by captopril but were abolished by chymostatin and markedly reduced by C41. In addition, we found that prior treatment of the patients with an ACE inhibitor did not affect the in vitro response to Ang I (in the absence or the presence of captopril) or to [Pro,¹¹D-Ala¹²] Ang I.

Conclusions— Our results reinforce the hypothesis that chymase is a major serine protease implicated in the ACE-independent production of Ang II in human arteries.

Key Words: angiotensin • arteries • vasoconstriction

This article has been cited by other articles:

				Y. Wang, Y. Gu, and D. F. Lewis Endothelial Angiotensin II Generation Induced by Placenta-derived Factors From Preeclampsia Reproductive Sciences, November 1, 2008; 15(9): 932 - 938. [Abstract] [PDF]

				P. C. Cristovam, C. P. Arnoni, M. C. C. de Andrade, D. E. Casarini, L. G. Pereira, N. Schor, and M. A. Boim ACE-Dependent and Chymase-Dependent Angiotensin II Generation in Normal and Glucose-Stimulated Human Mesangial Cells Experimental Biology and Medicine, August 1, 2008; 233(8): 1035 - 1043. [Abstract] [Full Text] [PDF]

				E. N. Lavrentyev, A. M. Estes, and K. U. Malik Mechanism of High Glucose Induced Angiotensin II Production in Rat Vascular Smooth Muscle Cells Circ. Res., August 31, 2007; 101(5): 455 - 464. [Abstract] [Full Text] [PDF]

				P. van der Harst, M. Volbeda, A. A. Voors, H. Buikema, S. Wassmann, M. Bohm, G. Nickenig, and W. H. van Gilst Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting Hypertension, December 1, 2004; 44(6): 930 - 934. [Abstract] [Full Text] [PDF]

				R. Chen, M. Iwai, L. Wu, J. Suzuki, L.-J. Min, T. Shiuchi, T. Sugaya, H.-W. Liu, T.-X. Cui, and M. Horiuchi Important Role of Nitric Oxide in the Effect of Angiotensin-Converting Enzyme Inhibitor Imidapril on Vascular Injury Hypertension, October 1, 2003; 42(4): 542 - 547. [Abstract] [Full Text] [PDF]

				X. R. Huang, W. Y. Chen, L. D. Truong, and H. Y. Lan Chymase Is Upregulated in Diabetic Nephropathy: Implications for an Alternative Pathway of Angiotensin II-Mediated Diabetic Renal and Vascular Disease J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1738 - 1747. [Abstract] [Full Text] [PDF]

				B. Tom, I. M. Garrelds, E. Scalbert, A. P.A. Stegmann, F. Boomsma, P. R. Saxena, and A.H. J. Danser ACE- Versus Chymase-Dependent Angiotensin II Generation in Human Coronary Arteries: A Matter of Efficiency? Arterioscler Thromb Vasc Biol, February 1, 2003; 23(2): 251 - 256. [Abstract] [Full Text] [PDF]